Ix Lp Seventh Mdv Partners,... Net Worth

The estimated Net Worth of Ix Lp Seventh Mdv Partners,... is at least $37.7 Million dollars as of 14 September 2016. Ix Partners owns over 62,977 units of Adamas Pharmaceuticals Inc stock worth over $33,141,429 and over the last 10 years Ix sold ADMS stock worth over $4,552,530.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Ix Partners ADMS stock SEC Form 4 insiders trading

Ix has made over 11 trades of the Adamas Pharmaceuticals Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently Ix bought 62,977 units of ADMS stock worth $1,037,861 on 14 September 2016.

The largest trade Ix's ever made was selling 119,556 units of Adamas Pharmaceuticals Inc stock on 28 May 2015 worth over $2,154,399. On average, Ix trades about 43,859 units every 50 days since 2015. As of 14 September 2016 Ix still owns at least 4,031,804 units of Adamas Pharmaceuticals Inc stock.

You can see the complete history of Ix Partners stock trades at the bottom of the page.

Insiders trading at Adamas Pharmaceuticals Inc

Over the last 11 years, insiders at Adamas Pharmaceuticals Inc have traded over $26,222,162 worth of Adamas Pharmaceuticals Inc stock and bought 1,128,061 units worth $17,799,399 . The most active insiders traders include Point Partners Llcjay Jeffr..., David L Mahoney, and William W. Ericson. On average, Adamas Pharmaceuticals Inc executives and independent directors trade stock every 25 days with the average trade being worth of $254,236. The most recent stock trade was executed by Vijay Shreedhar on 21 June 2021, trading 6,200 units of ADMS stock currently worth $31,992.

What does Adamas Pharmaceuticals Inc do?

Adamas Pharmaceuticals Inc. delivers innovative medicines that reduce the burden of neurological diseases on patients, caregivers and society. The company is a fully integrated company focused on growing a portfolio of therapies to address a range of neurological diseases.

Complete history of Ix Partners stock trades at Adamas Pharmaceuticals Inc

Adamas Pharmaceuticals Inc executives and stock owners

Adamas Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Neil McFarlane,
  Chief Executive Officer, Director
• Vijay Shreedhar,
  Chief Commercial Officer
• Christopher Prentiss,
  Chief Financial Officer, Chief Accounting Officer, Principal Financial Officer and Principal Accounting Officer
• David Mahoney,
  Lead Independent Chairman of the Board
• Martha Demski,
  Independent Director
• William Ericson,
  Independent Director
• Michael Bigham,
  Independent Director
• Mardi Dier,
  Independent Director
• Ivan Lieberburg,
  Independent Director
• John MacPhee,
  Director
• Anna Richo,
  Director
• Adrian Quartel,
  Chief Medical Officer
• Adrian Quartel M.D.,
  Chief Medical Officer
• Eric C. Schlezinger,
  Head of HR
• Dr. Jill M. Jene,
  Head of Corp. Devel., Strategy , Portfolio Planning & Alliance Management
• Sarah Mathieson,
  Head of Corp. Communications, Patient Advocacy & Engagement
• Richard H Booth,
  Director
• Rajiv Patni,
  Chief Medical Officer
• Ix Lp Seventh Mdv Partners,...,
  
• William J Dawson,
  Chief Financial Officer
• Natalie Mc Clure,
  SVP, Product Development
• Point Partners Llcjay Jeffr...,
  
• Richard King,
  Chief Operating Officer
• Gregory T Went,
  Chief Executive Officer
• Alfred G Merriweather,
  Chief Financial Officer
• Jennifer J Rhodes,
  General Counsel
• Capital Equity Investments,...,
  10% owner
• Sara Grootwassink Lewis,
  Director
• Jeffrey H Knapp,
  Chief Operating Officer
• Grace Shin,
  General Counsel
• Vii Lpmdv Ix Lp Seventh Mdv...,
  
• Ventures Management Iii, Ll...,
  
• Spyros Papapetropoulos,
  Director